The increased titres of EBV-specific IgA and IgG antibodies in the serum of NPC patients, as first reported in the 1970s, provide a rationale for the intervention (Henle and Henle, 1976; Ho et al., 1976). The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.